MDM2 and steatosis: In addition to the liver, inhibition of MDM2 by Nutlin‐3a exerts antifibrotic effects in hearts with myocardial infarction.[45] Indeed, our present study employed both genetic and pharmacological approaches to show that inactivation of MDM2 not only prevents steatosis but also limits inflammation and fibrosis in rodent models with MAFLD.